메뉴 건너뛰기




Volumn 5, Issue 1, 2013, Pages

Histone deacetylase inhibition in the treatment of acute myeloid leukemia: The effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents

Author keywords

Acute myeloid leukemia; Disease stabilization; Older patients; Valproic acid

Indexed keywords

4 PHENYLBUTYRIC ACID; 5 AZA 2' DEOXYCYTIDINE; ANTILEUKEMIC AGENT; AZACITIDINE; CYTARABINE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXYUREA; MERCAPTOPURINE; RETINOIC ACID; VALPROIC ACID;

EID: 84894797638     PISSN: 18687075     EISSN: 18687083     Source Type: Journal    
DOI: 10.1186/1868-7083-5-12     Document Type: Review
Times cited : (74)

References (133)
  • 1
    • 33751267902 scopus 로고    scopus 로고
    • Acute myeloid leukaemia
    • DOI 10.1016/S0140-6736(06)69780-8, PII S0140673606697808
    • Estey E, Döhner H: Acute myeloid leukaemia. Lancet 2006, 368:1894-1907. (Pubitemid 44794525)
    • (2006) Lancet , vol.368 , Issue.9550 , pp. 1894-1907
    • Estey, E.1    Dohner, H.2
  • 3
    • 79952086942 scopus 로고    scopus 로고
    • Therapeutic advances in acute myeloid leukemia
    • Burnett A, Wetzler M, Löwenberg B: Therapeutic advances in acute myeloid leukemia. J Clin Oncol 2011, 29:487-494.
    • (2011) J Clin Oncol , vol.29 , pp. 487-494
    • Burnett, A.1    Wetzler, M.2    Löwenberg, B.3
  • 9
    • 81255175041 scopus 로고    scopus 로고
    • Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: A novel paradigm for treatment assignment
    • Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA, Appelbaum FR, Kantarjian HA, Estey EH: Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol 2011, 29:4417-4423.
    • (2011) J Clin Oncol , vol.29 , pp. 4417-4423
    • Walter, R.B.1    Othus, M.2    Borthakur, G.3    Ravandi, F.4    Cortes, J.E.5    Pierce, S.A.6    Appelbaum, F.R.7    Kantarjian, H.A.8    Estey, E.H.9
  • 10
    • 84860257685 scopus 로고    scopus 로고
    • Roles of histone deacetylases in epigenetic regulation: Emerging paradigms from studies with inhibitors
    • Delcuve GP, Khan DH, Davie JR: Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors. Clin Epigenetics 2012, 4:5.
    • (2012) Clin Epigenetics , vol.4 , pp. 5
    • Delcuve, G.P.1    Khan, D.H.2    Davie, J.R.3
  • 11
    • 34548176264 scopus 로고    scopus 로고
    • Valproic acid for the treatment of myeloid malignancies
    • DOI 10.1002/cncr.22891
    • Kuendgen A, Gattermann N: Valproic acid for the treatment of myeloid malignancies. Cancer 2007, 110:943-954. (Pubitemid 47312858)
    • (2007) Cancer , vol.110 , Issue.5 , pp. 943-954
    • Kuendgen, A.1    Gattermann, N.2
  • 12
    • 0035992780 scopus 로고    scopus 로고
    • Valproate and valproate-analogues: Potent tools to fight against cancer
    • Blaheta RA, Nau H, Michaelis M, Cinatl J Jr: Valproate and valproate-analogues: potent tools to fight against cancer. Curr Med Chem 2002, 9:1417-1433. (Pubitemid 34823024)
    • (2002) Current Medicinal Chemistry , vol.9 , Issue.15 , pp. 1417-1433
    • Blaheta, R.A.1    Nau, H.2    Michaelis, M.3    Cinatl Jr., J.4
  • 14
    • 79751528245 scopus 로고    scopus 로고
    • Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia
    • Quintás-Cardama A, Santos FP, Garcia-Manero G: Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia 2011, 25:226-235.
    • (2011) Leukemia , vol.25 , pp. 226-235
    • Quintás-Cardama, A.1    Santos, F.P.2    Garcia-Manero, G.3
  • 16
    • 27144475816 scopus 로고    scopus 로고
    • Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors
    • DOI 10.1038/sj.leu.2403910, PII 2403910
    • Bradbury CA, Khanim FL, Hayden R, Bunce CM, White DA, Drayson MT, Craddock C, Turner BM: Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 2005, 19:1751-1759. (Pubitemid 41486152)
    • (2005) Leukemia , vol.19 , Issue.10 , pp. 1751-1759
    • Bradbury, C.A.1    Khanim, F.L.2    Hayden, R.3    Bunce, C.M.4    White, D.A.5    Drayson, M.T.6    Craddock, C.7    Turner, B.M.8
  • 17
    • 34547663854 scopus 로고    scopus 로고
    • Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia
    • DOI 10.3324/haematol.10758
    • Bug G, Schwarz K, Schoch C, Kampfmann M, Henschler R, Hoelzer D, Ottmann OG, Ruthardt M: Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia. Haematologica 2007, 92:542-545. (Pubitemid 350144299)
    • (2007) Haematologica , vol.92 , Issue.4 , pp. 542-545
    • Bug, G.1    Schwarz, K.2    Schoch, C.3    Kampfmann, M.4    Henschler, R.5    Hoelzer, D.6    Ottmann, O.G.7    Ruthardt, M.8
  • 18
    • 34547652768 scopus 로고    scopus 로고
    • Downregulation of c-Myc is critical for valproic acid-induced growth arrest and myeloid differentiation of acute myeloid leukemia
    • DOI 10.1016/j.leukres.2007.03.012, PII S0145212607000963
    • Cheng YC, Lin H, Huang MJ, Chow JM, Lin S, Liu HE: Downregulation of c-Myc is critical for valproic acid-induced growth arrest and myeloid differentiation of acute myeloid leukemia. Leuk Res 2007, 31:1403-1411. (Pubitemid 47212434)
    • (2007) Leukemia Research , vol.31 , Issue.10 , pp. 1403-1411
    • Cheng, Y.-C.1    Lin, H.2    Huang, M.-J.3    Chow, J.-M.4    Lin, S.5    Liu, H.E.6
  • 22
    • 84858290309 scopus 로고    scopus 로고
    • Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: Serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment
    • Fredly H, Reikvam H, Gjertsen BT, Bruserud O: Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: Serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment. Am J Hematol 2012, 87:368-376.
    • (2012) Am J Hematol , vol.87 , pp. 368-376
    • Fredly, H.1    Reikvam, H.2    Gjertsen, B.T.3    Bruserud, O.4
  • 23
    • 77957295583 scopus 로고    scopus 로고
    • Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia - A report of five case
    • Fredly H, Stapnes Bjørnsen C, Gjertsen BT, Bruserud Ø: Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia - a report of five case. Hematology 2010, 15:338-343.
    • (2010) Hematology , vol.15 , pp. 338-343
    • Fredly, H.1    Stapnes Bjørnsen, C.2    Gjertsen, B.T.3    Bruserud, Ø.4
  • 24
    • 77956924038 scopus 로고    scopus 로고
    • Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia
    • Goodyear O, Agathanggelou A, Novitzky-Basso I, Siddique S, McSkeane T, Ryan G, Vyas P, Cavenagh J, Stankovic T, Moss P, Craddock C: Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood 2010, 116:1908-1918.
    • (2010) Blood , vol.116 , pp. 1908-1918
    • Goodyear, O.1    Agathanggelou, A.2    Novitzky-Basso, I.3    Siddique, S.4    McSkeane, T.5    Ryan, G.6    Vyas, P.7    Cavenagh, J.8    Stankovic, T.9    Moss, P.10    Craddock, C.11
  • 26
    • 66649104180 scopus 로고    scopus 로고
    • Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes
    • Hauswald S, Duque-Afonso J, Wagner MM, Schertl FM, Lubbert M, Peschel C, Keller U, Licht T: Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes. Clin Cancer Res 2009, 15:3705-3715.
    • (2009) Clin Cancer Res , vol.15 , pp. 3705-3715
    • Hauswald, S.1    Duque-Afonso, J.2    Wagner, M.M.3    Schertl, F.M.4    Lubbert, M.5    Peschel, C.6    Keller, U.7    Licht, T.8
  • 27
    • 42549108601 scopus 로고    scopus 로고
    • Valproic acid sensitizes K562 erythroleukemia cells to TRAIL/Apo2L-induced apoptosis
    • Iacomino G, Medici MC, Russo GL: Valproic acid sensitizes K562 erythroleukemia cells to TRAIL/Apo2L-induced apoptosis. Anticancer Res 2008, 28:855-864. (Pubitemid 351578930)
    • (2008) Anticancer Research , vol.28 , Issue.2 A , pp. 855-864
    • Iacomino, G.1    Medici, M.C.2    Russo, G.L.3
  • 29
    • 70449449380 scopus 로고    scopus 로고
    • Human acute myeloid leukemia CD34 + CD38- stem cells are susceptible to allorecognition and lysis by single KIR-expressing natural killer cells
    • Langenkamp U, Siegler U, Jörger S, Diermayr S, Gratwohl A, Kalberer CP, Wodnar-Filipowicz A: Human acute myeloid leukemia CD34 + CD38- stem cells are susceptible to allorecognition and lysis by single KIR-expressing natural killer cells. Haematologica 2009, 94:1590-1594.
    • (2009) Haematologica , vol.94 , pp. 1590-1594
    • Langenkamp, U.1    Siegler, U.2    Jörger, S.3    Diermayr, S.4    Gratwohl, A.5    Kalberer, C.P.6    Wodnar-Filipowicz, A.7
  • 30
    • 84863781700 scopus 로고    scopus 로고
    • Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL
    • Leiva M, Moretti S, Soilihi H, Pallavicini I, Peres L, Mercurio C, Dal Zuffo R, Minucci S, de Thé H: Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL. Leukemia 2012, 26:1630-1637.
    • (2012) Leukemia , vol.26 , pp. 1630-1637
    • Leiva, M.1    Moretti, S.2    Soilihi, H.3    Pallavicini, I.4    Peres, L.5    Mercurio, C.6    Dal Zuffo, R.7    Minucci, S.8    De Thé, H.9
  • 32
    • 77949615011 scopus 로고    scopus 로고
    • Hydroxyurea upregulates NKG2D ligand expression in myeloid leukemia cells synergistically with valproic acid and potentially enhances susceptibility of leukemic cells to natural killer cell-mediated cytolysis
    • Lu X, Ohata K, Kondo Y, Espinoza JL, Qi Z, Nakao S: Hydroxyurea upregulates NKG2D ligand expression in myeloid leukemia cells synergistically with valproic acid and potentially enhances susceptibility of leukemic cells to natural killer cell-mediated cytolysis. Cancer Sci 2010, 101:609-615.
    • (2010) Cancer Sci , vol.101 , pp. 609-615
    • Lu, X.1    Ohata, K.2    Kondo, Y.3    Espinoza, J.L.4    Qi, Z.5    Nakao, S.6
  • 33
    • 80051614029 scopus 로고    scopus 로고
    • Molecular marks for epigenetic identification of developmental and cancer stem cells
    • Patra SK, Deb M, Patra A: Molecular marks for epigenetic identification of developmental and cancer stem cells. Clin Epigenetics 2011, 2:27-53.
    • (2011) Clin Epigenetics , vol.2 , pp. 27-53
    • Patra, S.K.1    Deb, M.2    Patra, A.3
  • 34
    • 64849109372 scopus 로고    scopus 로고
    • Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate
    • Poggi A, Catellani S, Garuti A, Pierri I, Gobbi M, Zocchi MR: Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate. Leukemia 2009, 23:641-648.
    • (2009) Leukemia , vol.23 , pp. 641-648
    • Poggi, A.1    Catellani, S.2    Garuti, A.3    Pierri, I.4    Gobbi, M.5    Zocchi, M.R.6
  • 35
    • 79952914715 scopus 로고    scopus 로고
    • Specific cellular signal-transduction responses to in vivo combination therapy with ATRA, valproic acid and theophylline in acute myeloid leukemia
    • Skavland J, Jørgensen KM, Hadziavdic K, Hovland R, Jonassen I, Bruserud Ø, Gjertsen BT: Specific cellular signal-transduction responses to in vivo combination therapy with ATRA, valproic acid and theophylline in acute myeloid leukemia. Blood Cancer J 2011, 1:e4.
    • (2011) Blood Cancer J , vol.1
    • Skavland, J.1    Jørgensen, K.M.2    Hadziavdic, K.3    Hovland, R.4    Jonassen, I.5    Bruserud, Ø.6    Gjertsen, B.T.7
  • 36
    • 78449301167 scopus 로고    scopus 로고
    • The effect of a histone deacetylase inhibitor - valproic acid - on nucleoli in human leukaemic myeloblasts
    • Smetana K, Zápotocký M: The effect of a histone deacetylase inhibitor - valproic acid - on nucleoli in human leukaemic myeloblasts. Folia Biol (Praha) 2010, 56: 201-205.
    • (2010) Folia Biol (Praha) , vol.56 , pp. 201-205
    • Smetana, K.1    Zápotocký, M.2
  • 37
    • 38449109278 scopus 로고    scopus 로고
    • Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in susceptibility to histone deacetylase inhibitors
    • Stapnes C, Ryningen A, Hatfield K, Øyan AM, Eide GE, Corbascio M, Kalland KH, Gjertsen BT, Bruserud Ø: Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in susceptibility to histone deacetylase inhibitors. Int J Oncol 2007, 31:1529-1538.
    • (2007) Int J Oncol , vol.31 , pp. 1529-1538
    • Stapnes, C.1    Ryningen, A.2    Hatfield, K.3    Øyan, A.M.4    Eide, G.E.5    Corbascio, M.6    Kalland, K.H.7    Gjertsen, B.T.8    Bruserud, Ø.9
  • 38
    • 63849224411 scopus 로고    scopus 로고
    • Involvement of PML nuclear bodies in CBP degradation through the ubiquitin-proteasome pathway
    • St-Germain JR, Chen J, Li Q: Involvement of PML nuclear bodies in CBP degradation through the ubiquitin-proteasome pathway. Epigenetics 2008, 3:342-349.
    • (2008) Epigenetics , vol.3 , pp. 342-349
    • St.-Germain, J.R.1    Chen, J.2    Li, Q.3
  • 39
    • 29144481615 scopus 로고    scopus 로고
    • Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia
    • Kuendgen A, Knipp S, Fox F, Strupp C, Hildebrandt B, Steidl C, Germing U, Haas R, Gattermann N: Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. Ann Hematol 2005, 84(Suppl 1):61-66.
    • (2005) Ann Hematol , vol.84 , Issue.SUPPL. 1 , pp. 61-66
    • Kuendgen, A.1    Knipp, S.2    Fox, F.3    Strupp, C.4    Hildebrandt, B.5    Steidl, C.6    Germing, U.7    Haas, R.8    Gattermann, N.9
  • 40
    • 29744454120 scopus 로고    scopus 로고
    • The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia
    • DOI 10.1002/cncr.21552
    • Kuendgen A, SchmidM, Schlenk R, Knipp S, Hildebrandt B, Steidl C, Germing U, Haas R, Dohner H, Gattermann N: The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 2006, 106:112-119. (Pubitemid 43032555)
    • (2006) Cancer , vol.106 , Issue.1 , pp. 112-119
    • Kuendgen, A.1    Schmid, M.2    Schlenk, R.3    Knipp, S.4    Hildebrandt, B.5    Steidl, C.6    Germing, U.7    Haas, R.8    Dohner, H.9    Gattermann, N.10
  • 41
    • 0019407488 scopus 로고
    • Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid
    • Breitman TR, Collins SJ, Keene BR: Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid. Blood 1981, 57:1000-1004. (Pubitemid 11050800)
    • (1981) Blood , vol.57 , Issue.6 , pp. 1000-1004
    • Breitman, T.R.1    Collins, S.J.2    Keene, B.R.3
  • 42
    • 41949111045 scopus 로고    scopus 로고
    • Acute promyelocytic leukemia: From highly fatal to highly curable
    • Wang ZY, Chen Z: Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008, 111: 2505-2515.
    • (2008) Blood , vol.111 , pp. 2505-2515
    • Wang, Z.Y.1    Chen, Z.2
  • 43
    • 80052914145 scopus 로고    scopus 로고
    • Treatment of acute promyelocytic leukemia without cytotoxic chemotherapy
    • Park JH, Tallman MS: Treatment of acute promyelocytic leukemia without cytotoxic chemotherapy. Oncology 2011, 25:733-741.
    • (2011) Oncology , vol.25 , pp. 733-741
    • Park, J.H.1    Tallman, M.S.2
  • 44
    • 52149092181 scopus 로고    scopus 로고
    • Clinical significance of the most common chromosome translocations in adult acute myeloid leukemia
    • Mrózek K, Bloomfield CD: Clinical significance of the most common chromosome translocations in adult acute myeloid leukemia. J Natl Cancer Inst Monogr 2008, 39:52-57.
    • (2008) J Natl Cancer Inst Monogr , vol.39 , pp. 52-57
    • Mrózek, K.1    Bloomfield, C.D.2
  • 45
    • 35348907310 scopus 로고    scopus 로고
    • PML-RARalpha inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia
    • Ohnishi K: PML-RARalpha inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia. Int J Clin Oncol 2007, 12:313-317.
    • (2007) Int J Clin Oncol , vol.12 , pp. 313-317
    • Ohnishi, K.1
  • 46
    • 21744442937 scopus 로고    scopus 로고
    • The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells
    • DOI 10.1038/sj.leu.2403773
    • Trus MR, Yang L, Suarez Saiz F, Bordeleau L, Jurisica I, Minden MD: The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells. Leukemia 2005, 19:1161-1168. (Pubitemid 40945999)
    • (2005) Leukemia , vol.19 , Issue.7 , pp. 1161-1168
    • Trus, M.R.1    Yang, L.2    Suarez, S.F.3    Bordeleau, L.4    Jurisica, I.5    Minden, M.D.6
  • 47
    • 58849158362 scopus 로고    scopus 로고
    • Valproic acid and all-trans retinoic acid: Meta-analysis of a palliative treatment regimen in AML and MDS patients
    • Bellos F, Mahlknecht U: Valproic acid and all-trans retinoic acid: meta-analysis of a palliative treatment regimen in AML and MDS patients. Onkologie 2008, 31:629-633.
    • (2008) Onkologie , vol.31 , pp. 629-633
    • Bellos, F.1    Mahlknecht, U.2
  • 49
    • 20544471661 scopus 로고    scopus 로고
    • Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid
    • DOI 10.1002/cncr.21132
    • Pilatrino C, Cilloni D, Messa E, Morotti A, Giugliano E, Pautasso M, Familiari U, Cappia S, Pelicci PG, Lo Coco F, Saglio G, Guerrasio A: Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid. Cancer 2005, 104:101-109. (Pubitemid 40847757)
    • (2005) Cancer , vol.104 , Issue.1 , pp. 101-109
    • Pilatrino, C.1    Cilloni, D.2    Messa, E.3    Morotti, A.4    Giugliano, E.5    Pautasso, M.6    Familiari, U.7    Cappia, S.8    Pelicci, P.G.9    Lo, C.F.10    Saglio, G.11    Guerrasio, A.12
  • 50
    • 22544466164 scopus 로고    scopus 로고
    • Treatment of elderly acute myeloid leukemia with valproic acid and all-trans retinoic acid
    • Raffoux E, Chaibi P, Dombret H, Degos L: Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia. Haematologica 2005, 90:986-988. (Pubitemid 41020306)
    • (2005) Haematologica , vol.90 , Issue.7 , pp. 986-988
    • Raffoux, E.1    Chaibi, P.2    Dombret, H.3    Degos, L.4
  • 51
    • 63349103376 scopus 로고    scopus 로고
    • A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid
    • Ryningen A, Stapnes C, Lassalle P, Corbascio M, Gjertsen BT, Bruserud O: A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid. Leuk Res 2009, 33:779-787.
    • (2009) Leuk Res , vol.33 , pp. 779-787
    • Ryningen, A.1    Stapnes, C.2    Lassalle, P.3    Corbascio, M.4    Gjertsen, B.T.5    Bruserud, O.6
  • 55
    • 33846988679 scopus 로고    scopus 로고
    • Treatment of acute promyelocytic leukemia by retinoids
    • Acute Promyelocytic Leukemia: Molecular Genetics, Mouse Models and Targeted Therapy
    • Fenaux P, Wang ZZ, Degos L: Treatment of acute promyelocytic leukemia by retinoids. Curr Top Microbiol Immunol 2007, 313:101-128. (Pubitemid 47400335)
    • (2007) Current Topics in Microbiology and Immunology , vol.313 , pp. 101-128
    • Fenaux, P.1    Wang, Z.Z.2    Degos, L.3
  • 58
    • 77449149374 scopus 로고    scopus 로고
    • Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia
    • Cashen AF, Schiller GJ, O'Donnell MR, DiPersio JF: Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 2010, 28:556-561.
    • (2010) J Clin Oncol , vol.28 , pp. 556-561
    • Cashen, A.F.1    Schiller, G.J.2    O'Donnell, M.R.3    DiPersio, J.F.4
  • 59
    • 55749110754 scopus 로고    scopus 로고
    • Demethylating agents in myeloid malignancies
    • Garcia-Manero G: Demethylating agents in myeloid malignancies. Curr Opin Oncol 2008, 20:705-710.
    • (2008) Curr Opin Oncol , vol.20 , pp. 705-710
    • Garcia-Manero, G.1
  • 62
    • 21844450205 scopus 로고    scopus 로고
    • Decitabine in acute myeloid leukemia
    • DOI 10.1053/j.seminhematol.2005.05.007, PII S0037196305000673, Emerging Role of Epigenetic Therapy: Focus on Decitabine
    • Lubbert M, Minden M: Decitabine in acute myeloid leukemia. Semin Hematol 2005, 42:S38-42. (Pubitemid 40961871)
    • (2005) Seminars in Hematology , vol.42 , Issue.SUPPL. 2
    • Lubbert, M.1    Minden, M.2
  • 67
    • 31444438952 scopus 로고    scopus 로고
    • Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome
    • DOI 10.1038/sj.leu.2404050, PII 2404050
    • Maslak P, Chanel S, Camacho LH, Soignet S, Pandolfi PP, Guernah I, Warrell R, Nimer S: Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. Leukemia 2006, 20:212-217. (Pubitemid 43148657)
    • (2006) Leukemia , vol.20 , Issue.2 , pp. 212-217
    • Maslak, P.1    Chanel, S.2    Camacho, L.H.3    Soignet, S.4    Pandolfi, P.P.5    Guernah, I.6    Warrell, R.7    Nimer, S.8
  • 68
    • 79952262759 scopus 로고    scopus 로고
    • Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
    • Wagner JM, Hackanson B, Lübbert M, Jung M: Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenetics 2010, 1:117-136.
    • (2010) Clin Epigenetics , vol.1 , pp. 117-136
    • Wagner, J.M.1    Hackanson, B.2    Lübbert, M.3    Jung, M.4
  • 71
    • 79951874108 scopus 로고    scopus 로고
    • Vorinostat in acute myeloid leukemia and myelodysplastic syndromes
    • Prebet T, Vey N: Vorinostat in acute myeloid leukemia and myelodysplastic syndromes. Expert Opin Investig Drugs 2011, 20:287-295.
    • (2011) Expert Opin Investig Drugs , vol.20 , pp. 287-295
    • Prebet, T.1    Vey, N.2
  • 73
    • 84860595206 scopus 로고    scopus 로고
    • Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia
    • Walter RB, Medeiros BC, Powell BL, Schiffer CA, Appelbaum FR, Estey EH: Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia. Haematologica 2012, 97:739-742.
    • (2012) Haematologica , vol.97 , pp. 739-742
    • Walter, R.B.1    Medeiros, B.C.2    Powell, B.L.3    Schiffer, C.A.4    Appelbaum, F.R.5    Estey, E.H.6
  • 75
    • 84860229552 scopus 로고    scopus 로고
    • The epigenetic effects of butyrate: Potential therapeutic implications for clinical practice
    • Berni Canani R, Di Costanzo M, Leone L: The epigenetic effects of butyrate: potential therapeutic implications for clinical practice. Clin Epigenetics 2012, 4:4.
    • (2012) Clin Epigenetics , vol.4 , pp. 4
    • Berni Canani, R.1    Di Costanzo, M.2    Leone, L.3
  • 76
    • 37249071337 scopus 로고    scopus 로고
    • Histone deacetylase inhibitors in cancer treatment: A review of the clinical toxicity and the modulation of gene expression in cancer cells
    • DOI 10.2174/138920107783018417
    • Bruserud Ø, Stapnes C, Ersvaer E, Gjertsen BT, Ryningen A: Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell. Curr Pharm Biotechnol 2007, 8:388-400. (Pubitemid 350268198)
    • (2007) Current Pharmaceutical Biotechnology , vol.8 , Issue.6 , pp. 388-400
    • Bruserud, O.1    Stapnes, C.2    Ersvaer, E.3    Gjertsen, B.T.4    Ryningen, A.5
  • 77
    • 33144481148 scopus 로고    scopus 로고
    • Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML
    • DOI 10.1517/14728222.10.1.51
    • Bruserud Ø, Stapnes C, Tronstad KJ, Ryningen A, Anensen N, Gjertsen BT: Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML. Expert Opin Ther Targets 2006, 10:51-68. (Pubitemid 43263266)
    • (2006) Expert Opinion on Therapeutic Targets , vol.10 , Issue.1 , pp. 51-68
    • Bruserud, O.1    Stapnes, C.2    Tronstad, K.J.3    Ryningen, A.4    Anensen, N.5    Gjertsen, B.T.6
  • 78
    • 72449142349 scopus 로고    scopus 로고
    • Cytosine arabinoside: Metabolism, mechanisms of resistance and clinical pharmacology
    • Edited by Peters GJ. Totowa, NJ: Humana Press
    • Hubeek I, Kaspers G-J L, Ossenkoppele GJ, Peters GJ: Cytosine arabinoside: metabolism, mechanisms of resistance and clinical pharmacology. In Deoxynucleoside Analogs in Cancer Therapy. Edited by Peters GJ. Totowa, NJ: Humana Press; 2006:119-152
    • (2006) Deoxynucleoside Analogs in Cancer Therapy , pp. 119-152
    • Hubeek, I.1    Kaspers, G.-J.L.2    Ossenkoppele, G.J.3    Peters, G.J.4
  • 80
    • 65549090436 scopus 로고    scopus 로고
    • Acute myelogenous leukemia
    • Shipley JL, Butera JN: Acute myelogenous leukemia. Exp Hematol 2009, 37:649-658.
    • (2009) Exp Hematol , vol.37 , pp. 649-658
    • Shipley, J.L.1    Butera, J.N.2
  • 81
    • 0023500812 scopus 로고
    • Low dose cytosine arabinoside in myelodysplasia and acute myelogenous leukemia: A review
    • Bolwell BJ, Cassileth PA, Gale RP: Low dose cytosine arabinoside in myelodysplasia and acute myelogenous leukemia: a review. Leukemia 1987, 1:575-579. (Pubitemid 18005687)
    • (1987) Leukemia , vol.1 , Issue.8 , pp. 575-579
    • Bolwell, B.J.1    Cassileth, P.A.2    Gale, R.P.3
  • 83
    • 79959702661 scopus 로고    scopus 로고
    • Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia
    • Gu LF, Zhang WG, Wang FX, Cao XM, Chen YX, He AL, Liu J, Ma XR: Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia. J Cancer Res Clin Oncol 2011, 137:997-1003.
    • (2011) J Cancer Res Clin Oncol , vol.137 , pp. 997-1003
    • Gu, L.F.1    Zhang, W.G.2    Wang, F.X.3    Cao, X.M.4    Chen, Y.X.5    He, A.L.6    Liu, J.7    Ma, X.R.8
  • 85
    • 27244459396 scopus 로고    scopus 로고
    • Aclarubicin and low-dose Cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: A multicenter study of 112 Chinese patients
    • Li JM, Shen Y, Wu DP, Liang H, Jin J, Chen FY, Song YP, Song EY, Qiu XF, Hou M, Qiu ZC, Shen ZX: Aclarubicin and low-dose Cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 Chinese patients. Int J Hematol 2005, 82:48 -54.
    • (2005) Int J Hematol , vol.82 , pp. 48-54
    • Li, J.M.1    Shen, Y.2    Wu, D.P.3    Liang, H.4    Jin, J.5    Chen, F.Y.6    Song, Y.P.7    Song, E.Y.8    Qiu, X.F.9    Hou, M.10    Qiu, Z.C.11    Shen, Z.X.12
  • 86
    • 71749097018 scopus 로고    scopus 로고
    • The combination of conventional chemotherapy with new targeted therapy in hematologic malignancies: The safety and efficiency of low-dose cytarabine supports its combination with new therapeutic agents in early clinical trials
    • Fredly H, Ersvaer E, Stapnes C, Gjertsen BT, Bruserud O: The combination of conventional chemotherapy with new targeted therapy in hematologic malignancies: the safety and efficiency of low-dose cytarabine supports its combination with new therapeutic agents in early clinical trials. Curr Cancer Ther Rev 2009, 5:243-255.
    • (2009) Curr Cancer Ther Rev , vol.5 , pp. 243-255
    • Fredly, H.1    Ersvaer, E.2    Stapnes, C.3    Gjertsen, B.T.4    Bruserud, O.5
  • 87
    • 33750322388 scopus 로고    scopus 로고
    • Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia
    • DOI 10.1007/s11899-006-0025-4
    • Dingli D, Tefferi A: Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia. Curr Hematol Malig Rep 2006, 1:69-74. (Pubitemid 44623867)
    • (2006) Current Hematologic Malignancy Reports , vol.1 , Issue.2 , pp. 69-74
    • Dingli, D.1    Tefferi, A.2
  • 88
    • 67349092776 scopus 로고    scopus 로고
    • Hydroxyurea and hydroxamic acid derivatives as antitumor drugs
    • Saban N, Bujak M: Hydroxyurea and hydroxamic acid derivatives as antitumor drugs. Cancer Chemother Pharmacol 2009, 64:213-221.
    • (2009) Cancer Chemother Pharmacol , vol.64 , pp. 213-221
    • Saban, N.1    Bujak, M.2
  • 90
    • 33947205565 scopus 로고    scopus 로고
    • A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment
    • DOI 10.1002/cncr.22496
    • Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK, Wheatley K: A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007, 109:1114-1124. (Pubitemid 46435390)
    • (2007) Cancer , vol.109 , Issue.6 , pp. 1114-1124
    • Burnett, A.K.1    Milligan, D.2    Prentice, A.G.3    Goldstone, A.H.4    McMullin, M.F.5    Hills, R.K.6    Wheatley, K.7
  • 92
    • 34547116188 scopus 로고    scopus 로고
    • Thiopurines, DNA damage, DNA repair and therapy-related cancer
    • Karran P: Thiopurines, DNA damage, DNA repair and therapy-related cancer. Br Med Bull 2006, 79-80:153-170.
    • (2006) Br Med Bull , vol.79-80 , pp. 153-170
    • Karran, P.1
  • 93
    • 84866631524 scopus 로고    scopus 로고
    • Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia
    • Adam De Beaumais T, Jacqz-Aigrain E: Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia. Eur J Clin Pharmacol 2012, 68:1233-1242.
    • (2012) Eur J Clin Pharmacol , vol.68 , pp. 1233-1242
    • Adam De Beaumais, T.1    Jacqz-Aigrain, E.2
  • 94
    • 33750445292 scopus 로고    scopus 로고
    • Treatment of acute myeloid leukemia patients aged more than 75 years: Results of the E-AML-01 trial of the Japanese Elderly Leukemia and Lymphoma Study Group (JELLSG)
    • DOI 10.1080/10428190600733317, PII P862K8M222K03H70
    • Mori M, Ohta M, Miyata A, Higashihara M, Oshimi K, Kimura H, Yagasaki F, Sunami K: Treatment of acute myeloid leukemia patients aged more than 75 years: results of the E-AML-01 trial of the Japanese Elderly Leukemia and Lymphoma Study Group (JELLSG). Leuk Lymphoma 2006, 47:2062-2069. (Pubitemid 44650081)
    • (2006) Leukemia and Lymphoma , vol.47 , Issue.10 , pp. 2062-2069
    • Mori, M.1    Ohta, M.2    Miyata, A.3    Higashihara, M.4    Oshimi, K.5    Kimura, H.6    Yagasaki, F.7    Sunami, K.8
  • 95
    • 29144468876 scopus 로고    scopus 로고
    • A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: The Japan Adult Leukemia Study Group AML97 study
    • DOI 10.1002/cncr.21493
    • Miyawaki S, Sakamaki H, Ohtake S, Emi N, Yagasaki F, Mitani K, Matsuda S, Kishimoto Y, Miyazaki Y, Asou N, Matsushima T, Takahashi M, Ogawa Y, Honda S, Ohno R, Japan Adult Leukemia Study Group AML 97 Study: A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study. Cancer 2005, 104:2726-2734. (Pubitemid 41799616)
    • (2005) Cancer , vol.104 , Issue.12 , pp. 2726-2734
    • Miyawaki, S.1    Sakamaki, H.2    Ohtake, S.3    Emi, N.4    Yagasaki, F.5    Mitani, K.6    Matsuda, S.7    Kishimoto, Y.8    Miyazaki, Y.9    Asou, N.10    Matsushima, T.11    Takahashi, M.12    Ogawa, Y.13    Honda, S.14    Ohno, R.15
  • 96
    • 84894763978 scopus 로고    scopus 로고
    • The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia
    • in press
    • Fredly H, Ersvaer E, Kittang AO, Tsykunova G, Gjertsen BT, Bruserud O: The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia. Clin Epigenetics. in press.
    • Clin Epigenetics
    • Fredly, H.1    Ersvaer, E.2    Kittang, A.O.3    Tsykunova, G.4    Gjertsen, B.T.5    Bruserud, O.6
  • 97
    • 84861359248 scopus 로고    scopus 로고
    • Valproic acid combined with cytosine arabinoside in elderly patients with acute myeloid leukemia has in vitro but limited clinical activity
    • Lane S, Gill D, McMillan NA, Saunders N, Murphy R, Spurr T, Keane C, Fan HM, Mollee P: Valproic acid combined with cytosine arabinoside in elderly patients with acute myeloid leukemia has in vitro but limited clinical activity. Leuk Lymphoma 2012, 53:1077-1083.
    • (2012) Leuk Lymphoma , vol.53 , pp. 1077-1083
    • Lane, S.1    Gill, D.2    McMillan, N.A.3    Saunders, N.4    Murphy, R.5    Spurr, T.6    Keane, C.7    Fan, H.M.8    Mollee, P.9
  • 98
    • 84894876074 scopus 로고    scopus 로고
    • Hyperleukocytosis and leukapheresis: A single centre experience with regard to apheresis technique and efficiency and a review of previous studies of leukapheresis in the treatment of acute myeloid leukemia
    • in press
    • Bruserud O, Liseth K, Stamnesfet S, Cacic DL, Melve GK, Kristoffersen E, Hervig T, Reikvam H: Hyperleukocytosis and leukapheresis: a single centre experience with regard to apheresis technique and efficiency and a review of previous studies of leukapheresis in the treatment of acute myeloid leukemia. Transfus Med. in press.
    • Transfus Med
    • Bruserud, O.1    Liseth, K.2    Stamnesfet, S.3    Cacic, D.L.4    Melve, G.K.5    Kristoffersen, E.6    Hervig, T.7    Reikvam, H.8
  • 99
    • 33344474444 scopus 로고    scopus 로고
    • FLT3-ITD-, but not BCR/ABL-transformed cells require concurrent Akt/mTor blockage to undergo apoptosis after histone deacetylase inhibitor treatment
    • DOI 10.1182/blood-2005-08-3317
    • Cai D, Wang Y, Ottmann OG, Barth PJ, Neubauer A, Burchert A: FLT3-ITD-, but not BCR/ABL-transformed cells require concurrent Akt/mTor blockage to undergo apoptosis after histone deacetylase inhibitor treatment. Blood 2006, 107:2094-2097. (Pubitemid 43289394)
    • (2006) Blood , vol.107 , Issue.5 , pp. 2094-2097
    • Cai, D.1    Wang, Y.2    Ottmann, O.G.3    Barth, P.J.4    Neubauer, A.5    Burchert, A.6
  • 101
    • 77955846351 scopus 로고    scopus 로고
    • Curcumin p38-dependently enhances the anticancer activity of valproic acid in human leukemia cells
    • Chen J, Wang G, Wang L, Kang J, Wang J: Curcumin p38-dependently enhances the anticancer activity of valproic acid in human leukemia cells. Eur J Pharm Sci 2010, 41:210-218.
    • (2010) Eur J Pharm Sci , vol.41 , pp. 210-218
    • Chen, J.1    Wang, G.2    Wang, L.3    Kang, J.4    Wang, J.5
  • 102
    • 47749083495 scopus 로고    scopus 로고
    • A novel effect of DNA methyltransferase and histone deacetylase inhibitors: NFkappaB inhibition in malignant myeloblasts
    • Fabre C, Grosjean J, Tailler M, Boehrer S, Ades L, Perfettini JL, de Botton S, Fenaux P, Kroemer G: A novel effect of DNA methyltransferase and histone deacetylase inhibitors: NFkappaB inhibition in malignant myeloblasts. Cell Cycle 2008, 7:2139-2145. (Pubitemid 352031516)
    • (2008) Cell Cycle , vol.7 , Issue.14 , pp. 2139-2145
    • Fabre, C.1    Grosjean, J.2    Tailler, M.3    Boehrer, S.4    Ades, L.5    Perfettini, J.-L.6    De Botton, S.7    Fenaux, P.8    Kroemer, G.9
  • 103
    • 65549136174 scopus 로고    scopus 로고
    • Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells
    • Fuchs O, Provaznikova D, Marinov I, Kuzelova K, Spicka I: Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells. Cardiovasc Hematol Disord Drug Targets 2009, 9:62-77.
    • (2009) Cardiovasc Hematol Disord Drug Targets , vol.9 , pp. 62-77
    • Fuchs, O.1    Provaznikova, D.2    Marinov, I.3    Kuzelova, K.4    Spicka, I.5
  • 105
    • 84868352661 scopus 로고    scopus 로고
    • Synergistic/additive interaction of valproic acid with bortezomib on proliferation and apoptosis of acute myeloid leukemia cells
    • Nie D, Huang K, Yin S, Li Y, Xie S, Ma L, Wang X, Wu Y, Xiao J: Synergistic/additive interaction of valproic acid with bortezomib on proliferation and apoptosis of acute myeloid leukemia cells. Leuk Lymphoma 2012, 53:2487-2495.
    • (2012) Leuk Lymphoma , vol.53 , pp. 2487-2495
    • Nie, D.1    Huang, K.2    Yin, S.3    Li, Y.4    Xie, S.5    Ma, L.6    Wang, X.7    Wu, Y.8    Xiao, J.9
  • 106
    • 33745280074 scopus 로고    scopus 로고
    • Synergistic induction of folate receptor beta by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: Mechanism and utility in enhancing selective growth inhibition by antifolates
    • DOI 10.1158/0008-5472.CAN-05-4048
    • Qi H, Ratnam M: Synergistic induction of folate receptor beta by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: mechanism and utility in enhancing selective growth inhibition by antifolates. Cancer Res 2006, 66:5875-5882. (Pubitemid 43927142)
    • (2006) Cancer Research , vol.66 , Issue.11 , pp. 5875-5882
    • Qi, H.1    Ratnam, M.2
  • 107
    • 84880787849 scopus 로고    scopus 로고
    • Inhibition of Mammalian target of rapamycin in human acute myeloid leukemia cells has diverse effects that depend on the environmental in vitro stress
    • Ryningen A, Reikvam H, Nepstad I, Paulsen Rye K, Bruserud Ø: Inhibition of Mammalian target of rapamycin in human acute myeloid leukemia cells has diverse effects that depend on the environmental in vitro stress. Bone Marrow Res 2012, 2012:329061.
    • (2012) Bone Marrow Res , vol.2012 , pp. 329061
    • Ryningen, A.1    Reikvam, H.2    Nepstad, I.3    Paulsen Rye, K.4    Bruserud, Ø.5
  • 108
    • 79960279715 scopus 로고    scopus 로고
    • Synergistic effect of bortezomib and valproic acid treatment on the proliferation and apoptosis of acute myeloid leukemia and myelodysplastic syndrome cells
    • Wang AH, Wei L, Chen L, Zhao SQ, Wu WL, Shen ZX, Li JM: Synergistic effect of bortezomib and valproic acid treatment on the proliferation and apoptosis of acute myeloid leukemia and myelodysplastic syndrome cells. Ann Hematol 2011, 90:917-931.
    • (2011) Ann Hematol , vol.90 , pp. 917-931
    • Wang, A.H.1    Wei, L.2    Chen, L.3    Zhao, S.Q.4    Wu, W.L.5    Shen, Z.X.6    Li, J.M.7
  • 109
    • 80051469142 scopus 로고    scopus 로고
    • Heat shock protein 90 inhibition results in altered downstream signaling of mutant KIT and exerts synergistic effects on Kasumi-1 cells when combining with histone deacetylase inhibitor
    • Yu W, Wang J, Jin J, Qian W, Qian J, Cheng Y, Wang L: Heat shock protein 90 inhibition results in altered downstream signaling of mutant KIT and exerts synergistic effects on Kasumi-1 cells when combining with histone deacetylase inhibitor. Leuk Res 2011, 35:1212-1218.
    • (2011) Leuk Res , vol.35 , pp. 1212-1218
    • Yu, W.1    Wang, J.2    Jin, J.3    Qian, W.4    Qian, J.5    Cheng, Y.6    Wang, L.7
  • 110
    • 68749099507 scopus 로고    scopus 로고
    • A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability
    • ten Cate B, Bremer E, de Bruyn M, Bijma T, Samplonius D, Schwemmlein M, Huls G, Fey G, Helfrich W: A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability. Leukemia 2009, 23:1389-1397.
    • (2009) Leukemia , vol.23 , pp. 1389-1397
    • Ten Cate, B.1    Bremer, E.2    De Bruyn, M.3    Bijma, T.4    Samplonius, D.5    Schwemmlein, M.6    Huls, G.7    Fey, G.8    Helfrich, W.9
  • 111
    • 77954622997 scopus 로고    scopus 로고
    • Levels of care: Defining best supportive care in elderly patients with acute myeloid leukemia
    • Ritchie EK, Roboz GJ: Levels of care: defining best supportive care in elderly patients with acute myeloid leukemia. Curr Hematol Malig Rep 2010, 5:95-100.
    • (2010) Curr Hematol Malig Rep , vol.5 , pp. 95-100
    • Ritchie, E.K.1    Roboz, G.J.2
  • 112
    • 0037158110 scopus 로고    scopus 로고
    • The outcomes and costs of acute myeloid leukemia among the elderly
    • DOI 10.1001/archinte.162.14.1597
    • Menzin J, Lang K, Earle CC, Kerney D, Mallick R: The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med 2002, 162:1597-1603. (Pubitemid 34773427)
    • (2002) Archives of Internal Medicine , vol.162 , Issue.14 , pp. 1597-1603
    • Menzin, J.1    Lang, K.2    Earle, C.C.3    Kerney, D.4    Mallick, R.5
  • 113
    • 33750949551 scopus 로고    scopus 로고
    • Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: Problems and approaches
    • Deschler B, de Witte T, Mertelsmann R, Lübbert M: Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Haematologica 2006, 91:1513-1522. (Pubitemid 44736118)
    • (2006) Haematologica , vol.91 , Issue.11 , pp. 1513-1522
    • Deschler, B.1    De Witte, T.2    Mertelsmann, R.3    Lubbert, M.4
  • 114
    • 33845991508 scopus 로고    scopus 로고
    • Cancer vaccines for patients with acute myeloid leukemia - Definition of leukemia-associated antigens and current clinical protocols targeting these antigens
    • Greiner J, Döhner H, Schmitt M: Cancer vaccines for patients with acute myeloid leukemia-definition of leukemia-associated antigens and current clinical protocols targeting these antigens. Haematologica 2006, 91:1653-1661. (Pubitemid 46039635)
    • (2006) Haematologica , vol.91 , Issue.12 , pp. 1653-1661
    • Greiner, J.1    Dohner, H.2    Schmitt, M.3
  • 116
    • 79954564425 scopus 로고    scopus 로고
    • Immunogenic apoptosis in human acute myeloid leukemia (AML): Primary human AML cells expose calreticulin and release heat shock protein (HSP) 70 and HSP90 during apoptosis
    • Fredly H, Ersvær E, Gjertsen BT, Bruserud O: Immunogenic apoptosis in human acute myeloid leukemia (AML): primary human AML cells expose calreticulin and release heat shock protein (HSP) 70 and HSP90 during apoptosis. Oncol Rep 2011, 25: 1549-1556.
    • (2011) Oncol Rep , vol.25 , pp. 1549-1556
    • Fredly, H.1    Ersvær, E.2    Gjertsen, B.T.3    Bruserud, O.4
  • 118
    • 33750354943 scopus 로고    scopus 로고
    • High HSP70-membrane expression on leukemic cells from patients with acute myeloid leukemia is associated with a worse prognosis [19]
    • DOI 10.1038/sj.leu.2404391, PII 2404391
    • Steiner K, Graf M, Hecht K, Reif S, Rossbacher L, Pfister K, Kolb HJ, Schmetzer HM, Multhoff G: High HSP70-membrane expression on leukemic cells from patients with acute myeloid leukemia is associated with a worse prognosis. Leukemia 2006, 20:2076-2079. (Pubitemid 44614913)
    • (2006) Leukemia , vol.20 , Issue.11 , pp. 2076-2079
    • Steiner, K.1    Graf, M.2    Hecht, K.3    Reif, S.4    Rossbacher, L.5    Pfister, K.6    Kolb, H.-J.7    Schmetzer, H.M.8    Multhoff, G.9
  • 119
    • 22144458740 scopus 로고    scopus 로고
    • Expression of heat-shock proteins is associated with major adverse
    • DOI 10.1016/j.leukres.2005.02.010, PII S014521260500086X
    • Thomas X, Campos L, Mounier C, Cornillon J, Flandrin P, Le QH, Piselli S, Guyotat D: Expression of heat-shock proteins is associated with major adverse prognostic factors in acute myeloid leukemia. Leuk Res 2005, 29:1049-1058. (Pubitemid 40982599)
    • (2005) Leukemia Research , vol.29 , Issue.9 , pp. 1049-1058
    • Thomas, X.1    Campos, L.2    Mounier, C.3    Cornillon, J.4    Flandrin, P.5    Le, Q.-H.6    Piselli, S.7    Guyotat, D.8
  • 121
    • 77954560509 scopus 로고    scopus 로고
    • Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: The hematological experience
    • Liseth K, Ersvaer E, Hervig T, Bruserud Ø: Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: the hematological experience. J Biomed Biotechnol 2010, 2010:692097.
    • (2010) J Biomed Biotechnol , vol.2010 , pp. 692097
    • Liseth, K.1    Ersvaer, E.2    Hervig, T.3    Bruserud, Ø.4
  • 123
    • 1242307289 scopus 로고    scopus 로고
    • Short- and long-term effects of acute myeloid leukemia on patient health-related quality of life
    • DOI 10.1016/S0305-7372(03)00142-7
    • Redaelli A, Stephens JM, Brandt S, Botteman MF, Pashos CL: Short- and long-term effects of acute myeloid leukemia on patient health-related quality of life. Cancer Treat Rev 2004, 30:103-117. (Pubitemid 38240090)
    • (2004) Cancer Treatment Reviews , vol.30 , Issue.1 , pp. 103-117
    • Redaelli, A.1    Stephens, J.M.2    Brandt, S.3    Botteman, M.F.4    Pashos, C.L.5
  • 125
    • 15244363923 scopus 로고    scopus 로고
    • Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome
    • DOI 10.1038/sj.leu.2403289
    • Sekeres MA, Stone RM, Zahrieh D, Neuberg D, Morrison V, De Angelo DJ, Galinsky I, Lee SJ: Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia 2004, 18:809-816. (Pubitemid 38500200)
    • (2004) Leukemia , vol.18 , Issue.4 , pp. 809-816
    • Sekeres, M.A.1    Stone, R.M.2    Zahrieh, D.3    Neuberg, D.4    Morrison, V.5    De Angelo, D.J.6    Galinsky, I.7    Lee, S.J.8
  • 126
    • 24744446425 scopus 로고    scopus 로고
    • Quality of life may be affected more by disease parameters and response to therapy than by haemoglobin changes
    • Wisløff F, Gulbrandsen N, Hjorth M, Lenhoff S, Fayers P: Quality of life may be affected more by disease parameters and response to therapy than by haemoglobin changes. Eur J Haematol 2005, 75:293-298.
    • (2005) Eur J Haematol , vol.75 , pp. 293-298
    • Wisløff, F.1    Gulbrandsen, N.2    Hjorth, M.3    Lenhoff, S.4    Fayers, P.5
  • 127
    • 33847065486 scopus 로고    scopus 로고
    • The Epigenomics of Cancer
    • DOI 10.1016/j.cell.2007.01.029, PII S0092867407001274
    • Jones PA, Baylin SB: The epigenomics of cancer. Cell 2007, 128:683-692. (Pubitemid 46273572)
    • (2007) Cell , vol.128 , Issue.4 , pp. 683-692
    • Jones, P.A.1    Baylin, S.B.2
  • 130
    • 0032948005 scopus 로고    scopus 로고
    • Synergy of demethylation and histone deacetylase inhibition in the re- expression of genes silenced in cancer
    • DOI 10.1038/5047
    • Cameron EE, Bachman KE, Myöhänen S, Herman JG, Baylin SB: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999, 21:103-107. (Pubitemid 29036293)
    • (1999) Nature Genetics , vol.21 , Issue.1 , pp. 103-107
    • Cameron, E.E.1    Bachman, K.E.2    Myohanen, S.3    Herman, J.G.4    Baylin, S.B.5
  • 131
    • 0037115392 scopus 로고    scopus 로고
    • Dependence of histone modifications and gene expression on DNA hypermethylation in cancer
    • Fahrner JA, Eguchi S, Herman JG, Baylin SB: Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res 2002, 62:7213-7218. (Pubitemid 36025241)
    • (2002) Cancer Research , vol.62 , Issue.24 , pp. 7213-7218
    • Fahrner, J.A.1    Eguchi, S.2    Herman, J.G.3    Baylin, S.B.4
  • 132
    • 84877152427 scopus 로고    scopus 로고
    • Epigenetic dysregulation of secreted frizzled-related proteins in myeloproliferative neoplasms complements the JAK2V617F-mutation
    • Bennemann K, Galm O, Wilop S, Schubert C, Brummendorf TH, Jost E: Epigenetic dysregulation of secreted frizzled-related proteins in myeloproliferative neoplasms complements the JAK2V617F-mutation. Clin Epigenetics 2012, 4:12.
    • (2012) Clin Epigenetics , vol.4 , pp. 12
    • Bennemann, K.1    Galm, O.2    Wilop, S.3    Schubert, C.4    Brummendorf, T.H.5    Jost, E.6
  • 133
    • 84856271833 scopus 로고    scopus 로고
    • Epigenetic abnormalities in myeloproliferative neoplasms: A target for novel therapeutic strategies
    • Mascarenhas J, Roper N, Chaurasia P, Hoffman R: Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies. Clin Epigenetics 2011, 2:197-212.
    • (2011) Clin Epigenetics , vol.2 , pp. 197-212
    • Mascarenhas, J.1    Roper, N.2    Chaurasia, P.3    Hoffman, R.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.